MARY LEYDA: Open Payments
NPI 1619534146 · EUGENE, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$754 in 36 payments from 9 companies in 2025. Trend: 2023 $1,449 · 2024 $1,114 · 2025 $754
Food & beverage: $754
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 7 | $198 |
| ABBVIE INC. | 8 | $164 |
| Otsuka America Pharmaceutical, Inc. | 6 | $98 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $72 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| Vanda Pharmaceuticals Inc. | 3 | $65 |
| E.R. Squibb & Sons, L.L.C. | 3 | $52 |
| Lundbeck LLC | 1 | $22 |
| Janssen Pharmaceuticals, Inc | 1 | $15 |
Products named: VRAYLAR, LYBALVI, REXULTI, CAPLYTA, Auvelity, FANAPT, ARISTADA, COBENFY.
Industry payments across OR — which companies pay providers there.
